Aviptadil with Phentolamine Mesilate
Brand names: Invicorp
Aviptadil with phentolamine mesilate is a combination intracavernosal injection used in the treatment of erectile dysfunction, typically when oral therapy is unsuitable or ineffective.
Adult dose
Dose adjustments
SPC section 4.2: no formal studies have been performed in patients with impaired renal function; no dose adjustment is printed.
SPC section 4.2: no formal studies have been performed in patients with impaired hepatic function; no dose adjustment is printed.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substances or to any of the excipients (section 4.3)
- Men for whom sexual activity is not advisable or is contraindicated due to organic disease (section 4.3)
- Conditions that might predispose to priapism, such as sickle cell anaemia or trait, multiple myeloma, or leukaemia (section 4.3)
- Anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie's disease (section 4.3)
- Penile implants (section 4.3)
- Not recommended in children (section 4.2); indicated in adult males only (section 4.1)
Side effects
- Approximately 10% of patients experience adverse reactions (section 4.8)
- Common: flushing (often observed but rarely problematic) (section 4.8)
- Uncommon: headache, dizziness, tachycardia, palpitations (section 4.8)
- Rare: priapism, prolonged erection; penile nodules/fibrosis following multiple injections (section 4.8)
- Very rare: myocardial infarction, angina pectoris (section 4.8)
- Injection-site bruising, haematoma and pain post injection (section 4.8; the frequency columns for these are not reliably readable in the PDF text, so none is assigned)
- Penile fibrosis (angulation, cavernosal fibrosis, fibrotic nodules, Peyronie's disease) may occur and may increase with duration of use (section 4.4)
Interactions
- Use with caution with anticoagulants such as heparins and warfarin, including oral anticoagulants such as dabigatran, rivaroxaban or apixaban (section 4.5)
- No clinical interaction observed with concomitant anti-hypertensive or other cardiovascular medication (section 4.5)
- Other treatments for erectile dysfunction (e.g. sildenafil) or drugs that induce erection (e.g. papaverine) should not be used with Invicorp because of the potential for prolonged duration of erections (sections 4.4, 4.6)
Monitoring
- Regular patient monitoring (e.g. every 3 months), particularly in the initial stages of self-injection therapy (section 4.2)
- Regular follow-up with careful examination of the penis to detect signs of penile fibrosis or Peyronie's disease; discontinue if penile angulation, cavernosal fibrosis or Peyronie's disease develops (section 4.4)
- Patients to report immediately any erection lasting a prolonged period such as 4 hours or longer; treatment of priapism should not be delayed more than 6 hours (section 4.4)
- Caution in severe cardiovascular or cerebrovascular conditions; discontinue if tachycardia occurs (section 4.4)
Clinical monograph
How it works
Aviptadil (a vasoactive intestinal polypeptide analogue) and phentolamine (an alpha-adrenoceptor antagonist) together promote cavernosal smooth muscle relaxation and increased arterial inflow, producing an erection.
Prescribing in practice
- Prolonged erection and priapism can occur and require prompt treatment to avoid permanent erectile tissue damage.
- The first dose should be given under supervision so that the patient can be taught correct self-injection technique.
- Avoid in conditions predisposing to priapism and in penile anatomical abnormalities or implants.
Monitoring
Monitor for prolonged erection, injection-site reactions and penile fibrosis with continued use.
Counselling the patient
- Seek urgent medical help for any erection lasting longer than the time advised by your clinician.
- Use correct aseptic self-injection technique and rotate the injection site as instructed.
Evidence & guidelines
Intracavernosal therapy for erectile dysfunction is an established second-line option supported by clinical use and the SPC.
Reference: NICE CKS Erectile dysfunction (2023); EAU Guidelines on Sexual and Reproductive Health (2024); Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Sequential Organ Failure Assessment (SOFA) Score · Sepsis / Organ Failure
- Multiple Organ Dysfunction Score (MODS) · Organ Failure Assessment
- Logistic Organ Dysfunction Score (LODS) · ICU Scoring
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Composite Pulmonary Embolism Shock (CPES) Score · Pulmonary Embolism
- EUROMACS-RHF Score for Right Heart Failure after LVAD · Heart Failure